Literature DB >> 17267549

Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension.

Carmelle V Remillard1, Donna D Tigno, Oleksandr Platoshyn, Elyssa D Burg, Elena E Brevnova, Diane Conger, Ann Nicholson, Brinda K Rana, Richard N Channick, Lewis J Rubin, Daniel T O'connor, Jason X-J Yuan.   

Abstract

The pore-forming alpha-subunit, Kv1.5, forms functional voltage-gated K(+) (Kv) channels in human pulmonary artery smooth muscle cells (PASMC) and plays an important role in regulating membrane potential, vascular tone, and PASMC proliferation and apoptosis. Inhibited Kv channel expression and function have been implicated in PASMC from patients with idiopathic pulmonary arterial hypertension (IPAH). Here, we report that overexpression of the Kv1.5 channel gene (KCNA5) in human PASMC and other cell lines produced a 15-pS single channel current and a large whole cell current that was sensitive to 4-aminopyridine. Extracellular application of nicotine, bepridil, correolide, and endothelin-1 (ET-1) all significantly and reversibly reduced the Kv1.5 currents, while nicotine and bepridil also accelerated the inactivation kinetics of the currents. Furthermore, we sequenced KCNA5 from IPAH patients and identified 17 single-nucleotide polymorphisms (SNPs); 7 are novel SNPs. There are 12 SNPs in the upstream 5' region, 2 of which may alter transcription factor binding sites in the promoter, 2 nonsynonymous SNPs in the coding region, 2 SNPs in the 3'-untranslated region, and 1 SNP in the 3'-flanking region. Two SNPs may correlate with the nitric oxide-mediated decrease in pulmonary arterial pressure. Allele frequency of two other SNPs in patients with a history of fenfluramine and phentermine use was significantly different from patients who have never taken the anorexigens. These results suggest that 1) Kv1.5 channels are modulated by various agonists (e.g., nicotine and ET-1); 2) novel SNPs in KCNA5 are present in IPAH patients; and 3) SNPs in the promoter and translated regions of KCNA5 may underlie the altered expression and/or function of Kv1.5 channels in PASMC from IPAH patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17267549     DOI: 10.1152/ajpcell.00405.2006

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  72 in total

Review 1.  The role of mitochondria in pulmonary vascular remodeling.

Authors:  Peter Dromparis; Gopinath Sutendra; Evangelos D Michelakis
Journal:  J Mol Med (Berl)       Date:  2010-08-24       Impact factor: 4.599

Review 2.  Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.

Authors:  Stephen L Archer; E Kenneth Weir; Martin R Wilkins
Journal:  Circulation       Date:  2010-05-11       Impact factor: 29.690

3.  KCNA5 gene polymorphism associate with idiopathic atrial fibrillation.

Authors:  Li Tian; Gang Liu; Le Wang; Mingqi Zheng; Yongjun Li
Journal:  Int J Clin Exp Med       Date:  2015-06-15

4.  Tetramerization domain mutations in KCNA5 affect channel kinetics and cause abnormal trafficking patterns.

Authors:  Elyssa D Burg; Oleksandr Platoshyn; Igor F Tsigelny; Beatriz Lozano-Ruiz; Brinda K Rana; Jason X-J Yuan
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-16       Impact factor: 4.249

Review 5.  Two-pore potassium channels in the cardiovascular system.

Authors:  Alison Gurney; Boris Manoury
Journal:  Eur Biophys J       Date:  2008-05-01       Impact factor: 1.733

Review 6.  The role of genetics in pulmonary arterial hypertension.

Authors:  Lijiang Ma; Wendy K Chung
Journal:  J Pathol       Date:  2016-11-29       Impact factor: 7.996

Review 7.  Genetics of systemic sclerosis-associated pulmonary arterial hypertension: recent progress and current concepts.

Authors:  Sanjiv J Shah
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

8.  ERRgamma regulates cardiac, gastric, and renal potassium homeostasis.

Authors:  William A Alaynick; James M Way; Stephanie A Wilson; William G Benson; Liming Pei; Michael Downes; Ruth Yu; Johan W Jonker; Jason A Holt; Deepak K Rajpal; Hao Li; Joan Stuart; Ruth McPherson; Katja S Remlinger; Ching-Yi Chang; Donald P McDonnell; Ronald M Evans; Andrew N Billin
Journal:  Mol Endocrinol       Date:  2009-12-04

Review 9.  Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect.

Authors:  Katherine A Cottrill; Stephen Y Chan
Journal:  Eur J Clin Invest       Date:  2013-04-26       Impact factor: 4.686

Review 10.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.